Aprea Therapeutics Reports Q3 2024 Financial Results; Cash $26.2M, Net Loss $3.8M

Aprea Therapeutics, Inc.

2024-Q3 EPS reported -$1.88

Cash and cash equivalents of $26.2 million as of Sept 30, 2024, providing at least twelve months of runway.
Operating loss of $4.1 million for Q3 2024 versus $3.5 million in Q3 2023; net loss of $3.8 million ($0.64 per share).
Phase 1 ACESOT-1051 trial of WEE1 inhibitor APR-1051 shows well-tolerated profile with no unexpected toxicities at subtherapeutic doses.
Phase 1/2a ABOYA-119 trial of ATR inhibitor ATRN-119 enrolling at dose level 6 (800 mg QD); twice-daily dosing added to protocol.
Engaged Philippe Pultar, MD as senior medical advisor in October 2024 to support APR-1051 development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.